Page 42 - GHES-2-2

Global Health Econ Sustain MDR-TB and the road ahead

Consent for publication Research Square

Not applicable. https://doi.org/10.21203/rs.3.rs-2192240/v1
Cox, H., & Furin, J. (2021). The incalculable costs of tuberculosis.
Availability of data The Lancet Global Health, 9(10):1337-1338.

Not applicable. https://doi.org/10.1016/S2214-109X(21)00345-4
References European Centre for Disease Prevention and Control.
(2023). Tuberculosis: Annual Epidemiological Report
Akalu, T.Y., Clements, A.C.A., Wolde, H.F., & Alene, K.A. (2023). for 2020. Available from: https://www.ecdc.europa.eu/
Economic burden of multidrug-resistant tuberculosis on en/publications-data/tuberculosis-surveillance-and-
patients and households: A global systematic review and monitoring-europe-2023-2021-data [Last accessed on
meta-analysis. Scientific Reports, 13(1):22361. 2024 Apr 04].
https://doi.org/10.1038/s41598-023-47094-9 Falzon, D., Zignol, M., Bastard, M., Floyd, K., & Kasaeva, T.
Alene, K.A., Clements, A.C.A., McBryde, E.S., Jaramillo, E., (2023). The impact of the COVID-19 pandemic on the
Lönnroth, K., Shaweno, D., et al. (2018). Mental health global tuberculosis epidemic. Frontiers in Immunology,
disorders, social stressors and health-related quality of life in 29(14):1234785.
patients with multidrug-resistant tuberculosis: A systematic https://doi.org/10.3389/fimmu.2023.1234785
review and meta-analysis. Journal of Infection, 77(5):357-367.
Ferreira, M.R.L., Bonfim, R.O., Bossonario, P.A., Maurin, V.P.,
https://doi.org/10.1016/j.jinf.2018.07.007 Valença, A.B.M., Abreu, P.D., et al. (2023). Social protection
Assebe, L.F., Reda, H.L., Wubeneh, A.D., Lerebo, W.T., & Lambert, as a right of people affected by tuberculosis: A scoping
S.M. (2015). The effect of isoniazid preventive therapy on review and conceptual framework. Infectious Diseases of
incidence of tuberculosis among HIV-infected clients under Poverty, 12(1):103.
pre-ART care, Jimma, Ethiopia: A retrospective cohort https://doi.org/10.1186/s40249-023-01157-1
study. BMC Public Health, 15:346.
Fitzpatrick, C., & Floyd, K. (2012). A systematic review of the cost
https://doi.org/10.1186/s12889-015-1719-0 and cost effectiveness of treatment for multidrug-resistant
Assefa, D.G., Dememew, Z.G., Zeleke, E.D., Manyazewal, T., & tuberculosis. Pharmacoeconomics, 30(1):63-80.
Bedru, A. (2024). Financial burden of tuberculosis diagnosis https://doi.org/10.2165/11595340-000000000-00000
and treatment for patients in Ethiopia: A systematic review
and meta-analysis. BMC Public Health, 24(1):260. Ghazy, R.M., El Saeh, H.M., Abdulaziz, S., Hammouda, E.A.,
Elzorkany, A.M., Khidr, H., et al. (2022). A systematic
https://doi.org/10.1186/s12889-024-17713-9 review and meta-analysis of the catastrophic costs incurred
Bu, Q., Qiang, R., Fang, L., Peng, X., Zhang, H., & Cheng, H. by tuberculosis patients. Scientific Reports, 12(1):558.
(2023). Global trends in the incidence rates of MDR and https://doi.org/10.1038/s41598-021-04345-x
XDR tuberculosis: Findings from the global burden of
disease study 2019. Frontiers in Pharmacology, 14:1156249. Grobler, L., Nagpal, S., Sudarsanam, T.D., & Sinclair, D. (2016).
Nutritional supplements for people being treated for active
https://doi.org/10.3389/fphar.2023.1156249 tuberculosis. Cochrane Database of Systematic Reviews,
Carter, D.J., Glaziou, P., Lonnroth, K., Siroka, A., Floyd, K., 2016(6):CD006086.
Weil, D., et al. (2018). The impact of social protection and https://doi.org/10.1002/14651858.CD006086.pub4
poverty elimination on global tuberculosis incidence:
A statistical modelling analysis of sustainable development Gunther, G., Guglielmetti, L., Leu, C., Lange, C., & van Leth, F.
Goal 1. Lancet Global Health, 6(5):514-522. (2023). Availability and costs of medicines for the treatment
of tuberculosis in Europe. Clinical Microbiology and
https://doi.org/10.1016/S2214-109X(18)30195-5
Infection, 29(1):77-84.
Cates, L., Crudu, V., Codreanu, A., Ciobanu, N., Fosburgh, H., https://doi.org/10.1016/j.cmi.2022.07.026
Cohen, T., et al. (2021). Laboratory costs of diagnosing TB
in a high multidrug-resistant TB setting. The International Gupta, A., Juneja, S., Babawale, V., Rustam Majidovich, N.,
Journal of Tuberculosis and Lung Disease, 25(3):228-230. Ndjeka, N., Thi Mai Nguyen, P., et al. (2024). Global
adoption of 6-month drug-resistant TB regimens: Projected
https://doi.org/10.5588/ijtld.20.0586
uptake by 2026. PLoS One, 19(1):e0296448.
Chen, Y., Zhiang, Y., Wu, Z., Xu, B., Chen, J., Sha, W., et al.(2022). https://doi.org/10.1371/journal.pone.0296448
Impact of Financial Support on Treatment Outcomes of
Multidrug-Resistant Tuberculosis: A Population-based, Ikram, A., Ali, A., Abbasi, S.H., Ashraf, N., Wali, S., Salman, M.,
Retrospective cohort Study in China. PREPRINT (Version 1). et al. (2020). Is Tuberculosis Treatment Truly Free? A study

Volume 2 Issue 2 (2024) 5 https://doi.org/10.36922/ghes.2876